Sitemap | Contact Us

Daiichi-Sankyo

Home > Terms of Use and Privacy Policy

Terms of Use and Privacy Policy

Sign Up for Updates

Be notified about site updates, educational opportunities, and more.

Sign Up Now

Terms of Use and Privacy Policy

The content of this site is protected under applicable copyright and trademark laws. You may print a single copy of the content for your own personal non-commercial use. The further copying, redistribution, or publication of any part of this site is prohibited. Daiichi Sankyo, Inc. makes no representations as to the availability, accuracy, or completeness of the content of this site.

Daiichi Sankyo, Inc. shall not be liable for any damages or injuries resulting from your access to, or inability to access, this site or from your reliance on any information at this site. Daiichi Sankyo, Inc. may collect data from you that you provide to us voluntarily such as your name, postal address, email address, telephone number, and other personal information. The information we collect is used to improve the content of our website, and may be used to contact you, via email or by regular mail, to provide you with information that we believe may be of interest to you. We do not sell or transfer the information you send to us to others outside our company, except that your data may be transferred to an outside fulfillment company for processing and mailing purposes, or for market research purposes. Data which is not personal, including questions, comments, ideas and suggestions, shall be deemed to be non-confidential, and Daiichi Sankyo, Inc. shall be free to disclose and use the same, without any obligations whatsoever towards you, for any purpose and through any means.

This site is controlled and operated from the United States. The information on this site is designed to comply with the laws of the United States and is intended for use by U.S. residents only. Daiichi Sankyo, Inc. makes no representation that materials in this site are appropriate or applicable for use in other countries. The information provided on this site is for general educational and informational purposes only. Such information is not meant to be a substitute for advice provided by a physician or other qualified healthcare professional.

Our site may provide links or references to other websites not affiliated with Daiichi Sankyo, Inc. Daiichi Sankyo, Inc. believes its links provide helpful information; however, Daiichi Sankyo, Inc. is not responsible for the content of such other sites and shall not be liable for any damages or injuries arising from your access to such sites. Links to other sites are provided only as a convenience to users of our site. This privacy policy is current as of the date on this page. Any changes made to this privacy policy will be posted on the website within thirty (30) days of the change.

Updated 10/07

IMPORTANT INFORMATION ABOUT WELCHOL

INDICATIONS

Welchol is indicated as an adjunct to diet and exercise to:

  • Reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia (Fredrickson Type IIa) as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor
  • Improve glycemic control in adults with type 2 diabetes mellitus

Important Limitations of Use

  • Welchol should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis
  • Welchol has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones
  • Welchol has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias

CONTRAINDICATIONS

Welchol is contraindicated in individuals with bowel obstruction, those with serum triglyceride (TG) concentrations of >500 mg/dL, or with a history of hypertriglyceridemia-induced pancreatitis.

WARNINGS AND PRECAUTIONS

Welchol can increase serum TG concentrations particularly when used in combination with sulfonylureas or insulin. Caution should be exercised when treating patients with TG levels >300 mg/dL. Welchol may decrease the absorption of fat-soluble vitamins A, D, E, and K. Patients on vitamin supplements should take their vitamins at least 4 hours prior to Welchol. Caution should be exercised when treating patients with a susceptibility to vitamin K or fat soluble vitamin deficiencies. Caution should also be exercised when treating patients with gastroparesis, gastrointestinal motility disorders, major gastrointestinal tract surgery, and when treating patients with dysphagia and swallowing disorders. Welchol reduces gastrointestinal absorption of some drugs. Drugs with a known interaction with colesevelam (glyburide, levothyroxine, and oral contraceptives [ethinyl estradiol, norethindrone]) should be administered at least 4 hours prior to Welchol. Drugs that have not been tested for interaction with colesevelam, especially those with a narrow therapeutic index, should also be administered at least 4 hours prior to Welchol. Alternatively, the physician should monitor drug levels of the co-administered drug.

ADVERSE REACTIONS

Primary Hyperlipidemia: In clinical trials, the adverse reactions observed in placebo – regardless of investigator assessment of causality were constipation (11.0% vs. 7.0%), dyspepsia (8.3% vs. 3.5%), nausea (4.2% vs. 3.9%), accidental injury (3.7% vs. 2.7%), asthenia (3.6% vs. 1.9%), pharyngitis (3.2% vs. 1.9%), flu syndrome (3.2% vs. 3.1%), rhinitis (3.2% vs. 3.1%) and myalgia (2.1% vs. 0.4%). Type 2 Diabetes: In clinical trials, the adverse reactions observed in placebo – regardless of investigator assessment of causality were constipation (8.7% vs. 2.0%), nasopharyngitis (4.1% vs. 3.6%), dyspepsia (3.9% vs. 1.4%), hypoglycemia (3.0% vs. 2.3%), nausea (3.0% vs. 1.4%) and hypertension (2.8% vs. 1.6%). Post-marketing experience: Due to the voluntary nature of these reports it is not possible to reliably estimate frequency or establish a causal relationship. Increased seizure activity or decreased phenytoin levels have been reported in patients receiving phenytoin concomitantly with Welchol. Reduced International Normalized Ratio (INR) has been reported in patients receiving warfarin concomitantly with Welchol.

PREGNANCY

Welchol is Pregnancy Category B.

The photos on this site depict models, not actual patients or healthcare professionals.

This information is intended for U.S. healthcare professionals only.
© 2008 Daiichi Sankyo, Inc.